Preprogen’s novel cell science technology is a proven pathology-based screening technology that allows thousands of cells that naturally shed from all surfaces within the female gynecologic tract to be collected intact on a unique, comfortable, Interlabial Collection Pad™ (ICP) designed to fit the contours of a woman’s body. The ICP in PadKit™ is hypoallergenic, non-toxic, non-invasive, and should be worn on non-menstrual days, over a 4-6-hour timeframe during the day or overnight.
Preprogen’s cell science technology is at the heart of PadKit, the first-and-only at-home gynecologic cancer cell collection screening kit that allows for the discreet collection of thousands of cells from the gynecologic tract. After the pad is worn, it is placed into a transportation tube that contains a novel transport solution and mailed back to Preprogen’s lab. At the lab, the transport solution that includes gynecologic cell pellets are screened and analyzed for abnormal cells, signs of infection, and a variety of additional assays including genomic testing.
In addition to the early detection of abnormal cancer cells and other women’s health issues, Preprogen’s patented fetal cell science technology will potentially provide unique insights into the development of the fetus and its cells throughout pregnancy. The goal is to create a standard screen for Fetal Fibronectin and to collect cells early for the detection of abnormal biomarkers such as Trisomy 21 (i.e., Down’s Syndrome), fetal rH factor, Tay Sachs disease, and Cystic Fibrosis. Currently, proper diagnosis requires the invasive and risky amniocentesis and chorionic villus sampling in advanced stages of pregnancy.
Preprogen’s cell science technology and the PadKit’s unique, comfortable, Interlabial Collection Pad (ICP) were discovered and developed by Shalom Z. Hirschman, M.D., Preprogen’s Chief Scientific Officer and Medical Director.
Preprogen's Margaret Blaetz
views magnified cells in
Preprogren's laboratory
